A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity.

Robert L Findling, Jacqui Lingler, Brieana M Rowles, Nora K McNamara, Joseph R Calabrese

Journal: Journal of child and adolescent psychopharmacology 2009;18(6):615-21

PMID: 19108666

Abstract

Children and adolescents who are the offspring of a bipolar parent and who first present with major depressive disorder (MDD) are at high risk for eventually developing bipolar disorder. In this report, the authors describe a group of 9 such high-risk children and adolescents with MDD, aged 7-16 years, who were randomized to receive treatment with either paroxetine monotherapy or combination paroxetine-divalproex sodium therapy. In the long-term management of depressive symptomatology in these patients, neither treatment appeared to be particularly effective. As a result, future treatment studies in this population appear to be warranted, not only due to the putative impending risk of developing bipolar disorder, but also the manifest risk of current depressive episodes.

Address: Department of Psychiatry, University Hospitals Case Medical Center/Case Western Reserve University, Cleveland, Ohio 44106, USA. [email protected]

DOI: 10.1089/cap.2008.018

Link outs

Free resources

Medical:

https://medlineplus.gov/bipolardisorder.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-HLA-B-1

Subscription / membership required

Full Text Sources:

https://www.liebertpub.com/doi/10.1089/cap.2008.01...

MeSH Terms: Adolescent, Antidepressive Agents, Second-Generation, Antimanic Agents, Bipolar Disorder, Child, Child of Impaired Parents, Depressive Disorder, Major, Drug Therapy, Combination, Female, Humans, Male, Paroxetine, Pilot Projects, Risk Factors, Valproic Acid